NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Society Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer – Presentation
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - SOUTH SAN FRANCISCO, Calif., March 15, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:...
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
–Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition– – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9...
Sutro Biopharma, Inc. Conference Call – Presentation
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel...
15th Annual World ADC London 2025 – Presentation
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the...
43rd Annual J.P. Morgan Healthcare Conference – Presentation
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established First-in-class Cell-free Capabilities at Commercial Scale
SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab...
